Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 4
2019 5
2021 1
2022 2
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year
Filters applied: . Clear all
Page 1
Antisense Therapy Attenuates Phospholamban p.(Arg14del) Cardiomyopathy in Mice and Reverses Protein Aggregation.
Eijgenraam TR, Stege NM, Oliveira Nunes Teixeira V, de Brouwer R, Schouten EM, Grote Beverborg N, Sun L, Später D, Knöll R, Hansson KM, Amilon C, Janzén D, Yeh ST, Mullick AE, van der Meer P, de Boer RA, Silljé HHW. Eijgenraam TR, et al. Among authors: amilon c. Int J Mol Sci. 2022 Feb 22;23(5):2427. doi: 10.3390/ijms23052427. Int J Mol Sci. 2022. PMID: 35269571 Free PMC article.
Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction.
Nelander K, Lagerstrom-Fermer M, Amilon C, Michaëlsson E, Heijer M, Kjaer M, Russell M, Han D, Lindstedt EL, Whatling C, Gan LM, Ericsson H. Nelander K, et al. Among authors: amilon c. Clin Transl Sci. 2021 May;14(3):812-819. doi: 10.1111/cts.12859. Epub 2021 May 2. Clin Transl Sci. 2021. PMID: 32770730 Free PMC article. Clinical Trial.
Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease.
Pettersen D, Broddefalk J, Emtenäs H, Hayes MA, Lemurell M, Swanson M, Ulander J, Whatling C, Amilon C, Ericsson H, Westin Eriksson A, Granberg K, Plowright AT, Shamovsky I, Dellsèn A, Sundqvist M, Någård M, Lindstedt EL. Pettersen D, et al. Among authors: amilon c. J Med Chem. 2019 May 9;62(9):4312-4324. doi: 10.1021/acs.jmedchem.8b02004. Epub 2019 Mar 26. J Med Chem. 2019. PMID: 30869888
Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator.
Erlandsson F, Albayaty M, Chialda L, Ericsson H, Amilon C, Nelander K, Jansson-Löfmark R, Wernevik L, Kjaer M, Bamberg K, Hartleib-Geschwindner J. Erlandsson F, et al. Among authors: amilon c. Br J Clin Pharmacol. 2018 Jul;84(7):1486-1493. doi: 10.1111/bcp.13562. Epub 2018 Apr 22. Br J Clin Pharmacol. 2018. PMID: 29468715 Free PMC article. Clinical Trial.
Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans.
Bhattacharya C, Sandinge AS, Bragg RA, Heijer M, Yan J, Andersson LC, Jurva U, Pelay-Gimeno M, Vaes WHJ, de Ligt RAF, Gränfors M, Amilon C, Lindstedt EL, Menakuru SR, Garkaviy P, Weidolf L, Gopaul VS. Bhattacharya C, et al. Among authors: amilon c. Drug Metab Dispos. 2023 Apr;51(4):451-463. doi: 10.1124/dmd.122.001100. Epub 2023 Jan 13. Drug Metab Dispos. 2023. PMID: 36639243
13 results